Drugs / DP001
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01969656 | ? → Jun 2004 | postmenopausal osteoporosis | Deltanoid Pharmaceuticals | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01922843 | Sep 2013 → May 2014 | end stage renal failure, secondary hyperparathyroidism | Deltanoid Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01653379 | Aug 2012 → Jul 2014 | secondary hyperparathyroidism of renal origin | Deltanoid Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00715676 | Mar 2007 → Dec 2008 | osteoporosis | Deltanoid Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DP001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00715676 ↗ |
| Known as | 2MD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01969656 ↗ |
| Action | Activate | “Vitamin D receptor agonist” CHEMBL605525 ↗ |
| Action | Inhibit | “suppress PTH synthesis” NCT01653379 ↗ |
| Modality | Small molecule | “DP001 is a vitamin D analog that has been shown to stimulate bone formation in pre-clinical studies.” NCT00715676 ↗ |
| Route | Oral | “oral, once daily” NCT00715676 ↗ |
| Target | PTH | “suppress PTH synthesis” NCT01653379 ↗ |
| Target | VDR | “Vitamin D receptor agonist” CHEMBL605525 ↗ |